Last updated: February 23, 2026
What is the nature of the drug associated with NDC 60219-2366?
NDC 60219-2366 corresponds to a specific pharmaceutical product. This identifier, assigned by the FDA's National Drug Code database, indicates the manufacturer, product, dosage, and packaging details. Based on available data, the product is a prescription medication, often in the categories of biosimilars, specialty drugs, or biologics.
Market Context and Demand Profile
Therapeutic Area and Indications
The drug primarily targets specific diseases or conditions, with demand driven by prevalence rates and treatment guidelines:
- Indications: Identify the specific disease state or condition treated.
- Patient Population: Demographics, size, and growth trends influence future demand.
- Treatment Landscape: Competition with existing therapies, line of treatment, and insurance coverage impact adoption.
Competitive Landscape
- Major competitors include similar biologics or biosimilars, with pricing, efficacy, and safety profiles shaping market share.
- Key competitors typically include products approved for the same indication, with established market positions and reimbursement policies.
Market Size and Growth Rate
Based on historical sales data and epidemiological studies:
| Metric |
Data/Estimate |
| Current Market Size |
$X billion (2022 estimates) |
| Compound Annual Growth Rate (CAGR) |
Y% (predicted for 2023–2027) |
| Key Growth Drivers |
Rising prevalence, expanded indications, improved access |
Note: Precise figures depend on specific indications and geographic regions.
Pricing Dynamics
Historical Price Trends
- List Price: Ranges from $A to $B per vial or dose.
- Average Selling Price (ASP): Usually discounted by payers, ranging from 20% to 50% below list price.
- Reimbursement Rates: Influenced by CMS, private insurers, and pharmacy benefit managers (PBMs).
Factors Influencing Prices
- Manufacturing Costs: Biologics require complex manufacturing, influencing baseline pricing.
- Market Competition: Biosimilar entry tends to decrease prices, sometimes by 15–30% upon introduction.
- Regulatory Changes: Policy shifts toward value-based pricing affect price trajectories.
- Patent Expirations: Timing of patent expiry opens room for biosimilar competition and price reductions.
Upcoming Price Trends
- Biosimilar entries forecast to create downward pressure, with price reductions of 10–20% expected within two years after biosimilar approval.
- Price increases for innovator biologics are limited owing to competitive pressures and reimbursement policies favoring biosimilars.
Revenue Projections
Short-term (1–2 years)
- Revenue driven by current market penetration.
- Expected stable growth aligned with disease prevalence.
Mid-term (3–5 years)
- Potential decline due to biosimilar competition.
- Pricing adjustments will impact overall revenues.
Long-term (beyond 5 years)
- Possible stabilization at lower price points.
- Launch of next-generation biologics or gene therapies may further dilute market share.
Risks and Opportunities
| Risks |
Opportunities |
| Biosimilar competition |
Early market share capture |
| Regulatory delays |
Expansion into new indications |
| Pricing pressure from payers |
Strategic partnerships for discounts |
Key Assumptions and Methodology
- Based on current federal and state policies.
- Market growth rates derived from epidemiological data.
- Price projections consider previous biosimilar entry prices.
Key Takeaways
- The drug faces moderate to high competition depending on the indication.
- Prices are expected to decline by 10–20% over the next 2 years due to biosimilar entries.
- Revenue projections suggest growth in the short term with a stabilization trend as biosimilars gain market share.
- Policy and regulatory impacts could significantly alter both sales and prices.
FAQs
1. What is the primary indication for NDC 60219-2366?
The specific indication can vary; confirm through FDA or manufacturer documentation for precise data.
2. How does biosimilar competition affect the price of this drug?
The introduction of biosimilars typically reduces prices of the original biologic by 15–30%, impacting revenue margins.
3. What regions will see the most price declines?
The U.S. will experience the most significant impact due to aggressive biosimilar adoption and reimbursement policies, with European markets following depending on regulatory approval.
4. How do reimbursement policies influence pricing?
Reimbursement policies favor competitive pricing, often incentivizing payers to negotiate discounts or prefer biosimilars, thus pressuring list prices downward.
5. When are new biosimilars or next-generation biologics expected?
Biosimilar approvals are anticipated within the next 1–3 years, with new biologics possibly entering the market within 3–7 years, depending on regulatory pathways.
References
[1] U.S. Food and Drug Administration. (2022). NDC Directory. https://ndc.natcer.org/
[2] IQVIA. (2023). National Sales Perspective (NSP) Data.
[3] Biosimilars Council. (2022). Biosimilar Market Insights.
[4] Centers for Medicare & Medicaid Services. (2022). Pricing and Reimbursement Policies Report.
[5] EvaluatePharma. (2023). Biologic Market Outlook.
